These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 277237)

  • 41. Peripheral neuropathy related to misonidazole: incidence and pathology.
    Urtasun RC; Chapman JD; Feldstein ML; Band RP; Rabin HR; Wilson AF; Marynowski B; Starreveld E; Shnitka T
    Br J Cancer Suppl; 1978 Jun; 3():271-5. PubMed ID: 209809
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of hypoxic radiosensitizer after mild hyperthermia in C3H mammary carcinoma.
    Ohizumi Y; Murayama C; Maezawa H; Mori T
    Tokai J Exp Clin Med; 1984 Oct; 9(4):331-7. PubMed ID: 6537042
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Testing of hypoxic cell radiosensitizers in vivo.
    Denekamp J
    Cancer Clin Trials; 1980; 3(2):139-48. PubMed ID: 7428137
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modification of the action of misonidazole. I. Effect of TAN on toxicity.
    Skov KA; Palcic B; Harrison IE; Skarsgard LD
    Int J Radiat Biol Relat Stud Phys Chem Med; 1980 Jun; 37(6):601-11. PubMed ID: 6968295
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical trials of radiosensitizers: what should we expect?
    Brown JM
    Int J Radiat Oncol Biol Phys; 1984 Mar; 10(3):425-9. PubMed ID: 6231272
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oncogenic transformation in vitro by the hypoxic cell sensitizer misonidazole.
    Miller RC; Hall EJ
    Br J Cancer; 1978 Sep; 38(3):411-7. PubMed ID: 708572
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effects of evening primrose oil on nerve function and capillarization in streptozotocin-diabetic rats: modulation by the cyclo-oxygenase inhibitor flurbiprofen.
    Cameron NE; Cotter MA; Dines KC; Robertson S; Cox D
    Br J Pharmacol; 1993 Aug; 109(4):972-9. PubMed ID: 8401950
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A biochemical neurotoxicity study relating the neurotoxic potential of metronidazole and nitrofurantoin with misonidazole.
    Rose GP; Dewar AJ; Stratford IJ
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):781-5. PubMed ID: 7107414
    [No Abstract]   [Full Text] [Related]  

  • 49. Misonidazole with dexamethasone rescue: an escalating dose toxicity study.
    Tanasichuk H; Urtasun RC; Fulton DS; Raleigh J
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1735-7. PubMed ID: 6480455
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Misonidazole with small dose fractions in an experimental osteosarcoma.
    van Putten LM; Smink T
    Br J Cancer Suppl; 1978 Jun; 3():246-9. PubMed ID: 277240
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor sensitizing effect by misonidazole in a clinically relevant radiation dose range.
    Grdina DJ; Thames HD; Milas L
    Int J Radiat Oncol Biol Phys; 1984 Mar; 10(3):379-83. PubMed ID: 6706731
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Present status of radiation sensitizers--hypoxic cell radiosensitizer].
    Murayama C; Mori T
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2135-41. PubMed ID: 2660744
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of the hypoxic radiosensitizer misonidazole on normal and irradiated epidermis.
    de Rey BM; Lanfranchi HE; Klein-Szanto AJ; Itoiz ME
    J Cutan Pathol; 1981 Apr; 8(2):89-95. PubMed ID: 7276290
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.
    Dische S; Saunders MI; Flockhart IR
    Br J Cancer Suppl; 1978 Jun; 3():318-21. PubMed ID: 209811
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Misonidazole and MTDQ in combination: cytotoxic and radiosensitizing properties in hypoxic mammalian cells.
    Astor M; Hall EJ
    Br J Cancer; 1979 May; 39(5):510-5. PubMed ID: 486306
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
    Coleman CN; Wasserman TH; Urtasun RC; Halsey J; Noll L; Hancock S; Phillips TL
    Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):389-93. PubMed ID: 2154420
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolic studies and neurotoxicity in tumors and brain of mice after hypoxic cell sensitizers.
    Streffer C; Tamulevicius P
    Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):571-5. PubMed ID: 8005816
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma.
    Bleehen NM; Wiltshire CR; Plowman PN; Watson JV; Gleave JR; Holmes AE; Lewin WS; Treip CS; Hawkins TD
    Br J Cancer; 1981 Apr; 43(4):436-42. PubMed ID: 7016157
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of misonidazole in situ on the radiation response of selected tumor subpopoulations.
    Grdina DJ; Sigdestad CP; Jovonovich JA
    Cancer Clin Trials; 1980; 3(2):149-54. PubMed ID: 7428138
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetic and metabolic studies of the hypoxic cell radiosensitizer misonidazole.
    Flockhart IR; Large P; Troup D; Malcolm SL; Marten TR
    Xenobiotica; 1978 Feb; 8(2):97-105. PubMed ID: 415443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.